80,000 New Lung Cancer Cases are Expected to Be Diagnosed in 2007 in the Seven Major Markets According to Report.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c69016) has announced the addition of "Stakeholder stakeholder n. a person having in his/her possession (holding) money or property in which he/she has no interest, right or title, awaiting the outcome of a dispute between two or more claimants to the money or property. Opinions: Small Cell Lung Cancer Lung Cancer, Small Cell Definition Small cell lung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description Lung cancer is divided into two main types: small cell and non-small cell. and Malignant Mesothelioma malignant mesothelioma Mesothelioma, see there - Limited R&D Activity Provides Opportunity for Early-Phase Pipeline Drugs" to their offering. SCLC SCLC abbr. Southern Christian Leadership Conference accounts for one-fifth of all lung tumour types. More than 80,000 new cases are expected to be diagnosed in 2007 in the seven major markets, although it is set to decrease due to changing smoking habits. Mesothelioma Mesothelioma Definition Mesothelioma is an uncommon disease that causes malignant cancer cells to form within the lining of the chest, abdomen, or around the heart. Its primary cause is believed to be exposure to asbestos. is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period latency period n. In psychoanalytic theory, the fourth stage of psychosexual development, extending from about age 5 to puberty, when a child apparently represses sexual urges and prefers to associate with members of the same sex. of the disease. Scope of this title: Overview of small cell lung cancer (SCLC) and mesothelioma, including epidemiology, staging, prognosis and unmet needs Review of current treatment modalities and physician opinion of existing and future treatment strategies Evaluation of key drugs currently used in the treatment of SCLC and mesothelioma Assessment of late-phase drugs in development for SCLC and mesothelioma including key opinion leaders view on their potential Highlights of this title: Despite decreasing incidence, unmet needs in SCLC remain high due to poor prognosis and lack of effective treatment. R&D interest in the disease is low; however, this represents an opportunity for developing companies in the SCLC market. Alimta is approved for other lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. indications including NSCLC NSCLC non (or cancer). NSCLC Non-small cell lung cancer, see there and mesothelioma. It is in a Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA trial in SCLC and we believe that, although unlikely to show significant efficacy advantage over current standard, Alimta may potentially demonstrate toxicity advantages, in which case, it may usurp u·surp v. u·surped, u·surp·ing, u·surps v.tr. 1. To seize and hold (the power or rights of another, for example) by force and without legal authority. See Synonyms at appropriate. 2. etoposide as standard therapy. Incidence of malignant mesothelioma may have peaked in the US but is set to increase over the next two decades in Europe and Japan due to the later uptake of asbestos in these markets. Nevertheless, overall incidence of mesothelioma remains low; as is the R&D interest in the disease. Reasons to order your copy: Evaluate opportunities and risks in the SCLC and mesothelioma markets by analyzing the clinical and commercial attractiveness of key drugs Assess key success factors that drive the SCLC and mesothelioma markets to estimate the potential of existing and pipeline drugs for the diseases Understand current and future competitive dynamics of SCLC and mesothelioma to determine the future size and scope of the markets Contents: ABOUT OUR HEALTHCARE About the Oncology pharmaceutical analysis team Nish Saini - Lead Analyst, Oncology Chapter 1. Executive summary Chapter 2. Sclc overview Chapter 3. Current sclc treatment options Chapter 4. Unmet needs in sclc Chapter 5. Sclc pipeline analysis Chapter 6. Malignant mesothelioma List of Tables List of Figures About Us About Our Healthcare About the Oncology analysis team Disclaimer List of Tables List of Figures For more information visit http://www.researchandmarkets.com/reports/c69016. Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion